Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma - World Journal of Surgical Oncology
Source : https://wjso.biomedcentral.com/articles/10.1186/s12957-023-02947-5
Background Diffuse large B cell lymphoma (DLBCL) is a more common non-Hodgkin lymphoma (NHL). This study aims to explore the prognostic value of PIM kinase family in DLBCL and its...
Conclusions: PIM kinase family may be a potential therapeutic target for DLBCL patients.
Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36827681/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The development of SPM and SHM leads to a poor survival in MM patients and is an important survivorship challenge. Given the median survival for MM continues to improve, continued vigilance is needed to assess the risks of SPM and SHM with maintenance therapy post-auto-HSCT.
Dual targeting of protein translation and nuclear protein export results in enhanced anti-myeloma effects - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36827679/
Selinexor (KPT-330) is a small molecule inhibitor of XPO1 (exportin 1, Chromosome Region Maintenance 1/CRM1), which mediates the transport of tumor suppressor proteins, oncogene mRNAs and other proteins involved in...
Conclusions: These results suggest a synergistic anti-MM effects of selinexor combined with eIF4E inhibitors in vitro. Our work provides a better understanding of the potential mechanism of resistance to selinexor and a rationale for combining selinexor with eIF4E inhibitors for the treatment of MM.
Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36820285/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: We suggest that a prognostic scoring system using MYC expression and soluble interleukin receptor -2 level is useful for the prediction of prognosis, contributing to further stratification in DLBCL-NOS.
Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36819165/
The rituximab biosimilar CT-P10 is approved for the treatment of non-Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT-P10 and reference rituximab. However, real-world data relating to treatment in...
Conclusions: This international, multicenter study provides real-world data on the safety and effectiveness profile of CT-P10 for DLBCL treatment and supports the adoption of CT-P10 for the treatment of DLBCL